The merger, which values NuVasive at $3.1 billion, was first announced in February. Both companies posted revenue growth in their most recent quarterly reports.
Under the merger, Globus Medical grew its board of directors from eight to 11 and added John DeFord, PhD; Leslie Norwalk and Daniel J. Wolterman.
“We’re thrilled to begin our journey together to create a leading global musculoskeletal company,” Globus Medical CEO Dan Scavilla said in a news release. “With a relentless focus on changing patient lives, we’re combining our differentiated portfolios and talented teams to reach more customers as we advance spine and orthopedic care globally.”
